Status:

RECRUITING

Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR

Lead Sponsor:

German Heart Institute

Collaborating Sponsors:

Medical Statistics, University Medicine of Goettingen

AstraZeneca

Conditions:

Heart Failure With Preserved Ejection Fraction (HFPEF)

Eligibility:

All Genders

40-69 years

Brief Summary

Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities/metr...

Detailed Description

The WE-CARE-HF-CMR-study is a cross-sectional, nationwide prospective, community-based observational study to improve the diagnosis of heart failure in urban populations with characteristic risk facto...

Eligibility Criteria

Inclusion

  • Asymptomatic subjects with:
  • chronic diabetes mellitus (known/diagnosed and/or antidiabetic medication and/or elevated HbA1C) and/or
  • renal impairment (known/diagnosed CKD and/or in laboratory CKD III° or higher) and/or
  • Hypertension (known/diagnosed and/or antihypertensive medication/treatment) and/or
  • Hypercholesterolaemia (known/diagnosed and/or antilipid medication/treatment) and/or
  • Obesity (known/diagnosed and/or BMI \> 30 (kg/m²)) and/or
  • Smoker (known/diagnosed and/or current/previous and/or medication/treatment)
  • Age 40-69 years
  • female or male or diverse sex
  • Ability to provide informed consent
  • Provision of Informed Consent

Exclusion

  • Inability to provide written informed consent
  • Diagnosed heart failure or previously detected reduced ejection fraction
  • General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)
  • Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure
  • Haemodynamically unstable participants (heart rate \< 45/min, systolic blood pressure \< 90 mmHg)
  • Claustrophobia
  • Sensorineural hearing loss of 30 dB or more and tinnitus
  • Acute mental disorders requiring therapy
  • In the presence of pregnancy

Key Trial Info

Start Date :

September 13 2025

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2035

Estimated Enrollment :

450 Patients enrolled

Trial Details

Trial ID

NCT07185100

Start Date

September 13 2025

End Date

December 31 2035

Last Update

September 22 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Deutsches Herzzentrum der Charité

Berlin, Germany, 13353